2089251-33-0

Basic information

• Product Name: heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate
• CAS NO: 2089251-33-0
• Molecular Weight: 710.178
• Mol File: 2089251-33-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate(CAS DataBase Reference)
• NIST Chemistry Reference: heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate(2089251-33-0)
• EPA Substance Registry System: heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate(2089251-33-0)

Safety Data

• Hazardous Substances Data: 2089251-33-0(Hazardous Substances Data)

Usage

General Description

Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate is a chemical compound with a long hydrocarbon chain and a hydrophilic head group. The compound belongs to the class of ester compounds and is derived from a fatty acid and an amino alcohol. It is commonly used as an emulsifier, helping to mix oil and water-based ingredients in various products such as cosmetics, pharmaceuticals, and food. heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate has surfactant properties, allowing it to reduce the surface tension between two substances and improve the stability and consistency of the final product. It also provides a smooth and creamy texture in cosmetic and personal care products.

Upstream product

• 17049-49-9 octylmagnesium bromide 
• 124-19-6 nonan-1-al 
• 143-08-8 nonyl alcohol 
• 624-08-8 9-heptadecanol 
• 17696-11-6 8-bromooctanoic acid 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY

The present application provides a composition comprising (1) a lipid composition comprising an ionizable amino lipid and a quaternary amine compound and (2) a polynucleotide. The present application also provides a composition comprising (1) a lipid composition comprising an asymmetric phospholipid, an ionizable amino lipid, and optionally a quaternary amine compound and (2) a polynucleotide, wherein the composition is formulated for intratumoral delivery of the polynucleotide. The present application further provides pharmaceutical compositions for intratumoral delivery comprising (1) a lipid composition comprising a compound of formula (I) and (2) therapeutic agent or a polynucleotide encoding the therapeutic agent, e.g., an mRNA encoding a therapeutic protein or a fragment thereof. Further provided is a method of increasing retention of a polynucleotide in a tumor tissue by using such a composition.

COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.